Effects of Streptozotocin-Induced Diabetes on Proliferation and Differentiation Abilities of Mesenchymal Stem Cells Derived from Subcutaneous and Visceral Adipose Tissues

Abstract

Introduction: Accumulated evidence indicates that there are intrinsic differences between adipose tissue-derived stem cells (ASCs) obtained from different body fat depots. Here, we compared the proliferation and multipotency of subcutaneous ASCs (SC-ASCs) and epididymal ASCs (ED-ASCs) before and after induction of diabetes by streptozotocin.

Methods: The adipogenic and osteogenic abilities of rat SC-ASCs and ED-ASCs were evaluated using Oil Red O and Alizarin Red staining, respectively. The expression of adipocyte (PPAR-γ, LPL) and osteoblast (ALP, SPP1) specific mRNAs was evaluated by quantitative real-time PCR. MTT test was used for determination of cell proliferation capacity.

Results: The proliferation of SC-ASCs was higher than ED-ASCs, both before and after diabetes induction (P<0.05). Diabetes increased the proliferative capability of SC-ASCs (P<0.05) but not ED-ASCs. Before diabetes, both adipogenic and osteogenic differentiation of SC-ASCs were higher than ED-ASCs (P<0.05). After diabetes, both SC-ASCs and ED-ASCs were able to differentiate into adipocyte and osteoblast, but the levels of differentiation were higher in SC-ASCs than in ED-ASCs (P<0.05). Diabetes decreased the expression of PPAR-γ and LPL, but increased the SPP1 and ALP expression in both SC-ASCs and ED-ASCs.

Conclusion: Our data suggested that diabetes increases the proliferation of ASCs but decreases their adipogenic differentiation. Also, SC-ASCs have higher proliferation and differentiation abilities than ED-ASCs in normal and diabetic conditions so can be more preferable for cell therapy.

Key words

diabetes - differentiation - proliferation - stem cell - subcutaneous - visceral

• References

• 1 Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006; 98: 1076-1084
• 2 Baksh D, Song L, Tuan RS. Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med 2004; 8: 301-316
• 3 You DH, Nam MJ. Effects of human epidermal growth factor gene-transfected mesenchymal stem cells on fibroblast migration and proliferation. Cell Prolif 2013; 46: 408-415
• 4 Orbay H, Tobita M, Mizuno H. Mesenchymal stem cells isolated from adipose and other tissues: basic biological properties and clinical applications. Stem Cells Int 2012; 2012: 461718
• 5 Ikegame Y, Yamashita K, Hayashi S et al. Comparison of mesenchymal stem cells from adipose tissue and bone marrow for ischemic stroke therapy. Cytotherapy 2011; 13: 675-685
• 6 Kern S, Eichler H, Stoeve J et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem cells (Dayton, Ohio) 2006; 24: 1294-1301
• 7 Lee MJ, Wu Y, Fried SK. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Mol Aspects Med 2013; 34: 1-11
• 8 Lin G, Wang G, Liu G et al. Treatment of type 1 diabetes with adipose tissue-derived stem cells expressing pancreatic duodenal homeobox 1. Stem Cell Dev 2009; 18: 1399-1406
• 9 Volarevic V, Arsenijevic N, Lukic ML et al. Concise review: Mesenchymal stem cell treatment of the complications of diabetes mellitus. Stem cells 2011; 29: 5-10
• 10 Trivedi HL, Vanikar AV, Thakker U et al. Human adipose tissue-derived mesenchymal stem cells combined with hematopoietic stem cell transplantation synthesize insulin. Transplan Proc 2008; 40: 1135-1139
• 11 Thakkar UG, Trivedi HL, Vanikar AV et al. Insulin-secreting adipose-derived mesenchymal stromal cells with bone marrow-derived hematopoietic stem cells from autologous and allogenic sources for type 1 diabetes mellitus. Cytotherapy 2015; 17: 940-947
• 12 Joe AW, Yi L, Even Y et al. Depot-specific differences in adipogenic progenitor abundance and proliferative response to high-fat diet. Stem cells 2009; 27: 2563-2570
• 13 Requicha JF, Viegas CA, Albuquerque CM et al. Effect of anatomical origin and cell passage number on the stemness and osteogenic differentiation potential of canine adipose-derived stem cells. Stem Cell Rev 2012; 8: 1211-1222
• 14 Toyoda M, Matsubara Y, Lin K et al. Characterization and comparison of adipose tissue-derived cells from human subcutaneous and omental adipose tissues. Cell Biochem Func 2009; 27: 440-447
• 15 Ghorbani A, Varedi M, Hadjzadeh MA et al. Type-1 diabetes induces depot-specific alterations in adipocyte diameter and mass of adipose tissues in the rat. Exp Clin Endocrinol Diabetes 2010; 118: 442-428
• 16 Ghorbani A, Omrani GR, Hadjzadeh MA et al. Proinsulin C-peptide inhibits lipolysis in diabetic rat adipose tissue through phosphodiestrase-3B enzyme. Horm Metab Res 2013; 45: 221-225
• 17 Ghorbani A, Jalali SA, Varedi M. Isolation of adipose tissue mesenchymal stem cells without tissue destruction: a non-enzymatic method. Tissue Cell 2014; 46: 54-58
• 18 Feizpour A, Boskabady MH, Ghorbani A. Adipose-derived stromal cell therapy affects lung inflammation and tracheal responsiveness in guinea pig model of COPD. Plos One 2014; 9: e108974
• 19 Yu G, Floyd ZE, Wu X et al. Adipogenic differentiation of adipose-derived stem cells. Methods Mol Biol 2011; 702: 193-200
• 20 Aguena M, Dalto Fanganiello R, Tissiani LAL et al. Optimization of parameters for a more efficient use of adipose-derived stem cells in regenerative medicine therapies. Stem cells Int 2012; 2012: 7
• 21 Ghorbani A, Rajaei Z, Zendehbad SB. Effects of fenugreek seeds on adipogenesis and lipolysis in normal and diabetic rats. Pakistan J Biol Sci 2014; 17: 523-528
• 22 Hsu LW, Goto S, Nakano T et al. The effect of exogenous histone H1 on rat adipose-derived stem cell proliferation, migration, and osteogenic differentiation in vitro. J Cell Physiol 2012; 227: 3417-3425
• 23 Alford AI, Reddy AB, Goldstein SA et al. Two molecular weight species of thrombospondin-2 are present in bone and differentially modulated in fractured and nonfractured tibiae in a murine model of bone healing. Calcified tissue Int 2012; 90: 420-428
• 24 Pevsner-Fischer M, Morad V, Cohen-Sfady M et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 2007; 109: 1422-1432
• 25 Baglioni S, Cantini G, Poli G et al. Functional differences in visceral and subcutaneous fat pads originate from differences in the adipose stem cell. Plos One 2012; 7: e36569
• 26 Ferrer-Lorente R, Bejar MT, Badimon L. Notch signaling pathway activation in normal and hyperglycemic rats differs in the stem cells of visceral and subcutaneous adipose tissue. Stem Cells Dev 2014; 23: 3034-3048
• 27 Stolzing A, Sellers D, Llewelyn O et al. Diabetes induced changes in rat mesenchymal stem cells. Cells Tissues Organs 2012; 191: 453-465
• 28 Ferrer-Lorente R, Bejar MT, Tous M et al. Systems biology approach to identify alterations in the stem cell reservoir of subcutaneous adipose tissue in a rat model of diabetes: effects on differentiation potential and function. Diabetologia 2014; 57: 246-256
• 29 Jumabay M, Moon JH, Yeerna H et al. Effect of diabetes mellitus on adipocyte-derived stem cells in rat. J Cell Physiol 2015; 230: 2821-2828
• 30 Tchkonia T, Giorgadze N, Pirtskhalava T et al. Fat depot-specific characteristics are retained in strains derived from single human preadipocytes. Diabetes 2006; 55: 2571-2578
• 31 Minteer DM, Young MT, Lin YC et al. Analysis of type II diabetes mellitus adipose-derived stem cells for tissue engineering applications. J. Tissue Eng 2015; 6: 1-12
• 32 Oliva-Olivera W, Leiva Gea A, Lhamyani S et al. Differences in the osteogenic differentiation capacity of omental adipose-derived stem cells in obese patients with and without metabolic syndrome. Endocrinology 2015; 156: 4492-4501
• 33 Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Physical Ther 2008; 88: 1254-1264
• 34 Brietzke SA. Oral antihyperglycemic treatment options for type 2 diabetes mellitus. Med Clin N Am 2015; 99: 87-106
• 35 Meah F, Juneja R. Insulin tactics in type 2 diabetes. Med Clin N Am 2015; 99: 157-186
• 36 Tzoulaki I, Molokhia M, Curcin V et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ (Clinical research ed) 2009; 339: b4731
• 37 Lind M, Svensson A-M, Kosiborod M et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2014; 371: 1972-1982
• 38 Godfrey KJ, Mathew B, Bulman JC et al. Stem cell-based treatments for type 1 diabetes mellitus: bone marrow, embryonic, hepatic, pancreatic and induced pluripotent stem cells. Diabetic Med 2012; 29: 14-23
• 39 Chhabra P, Brayman KL. Stem cell therapy to cure type 1 diabetes: from hype to hope. Stem Cell Translat Med 2013; 2: 328-336
• 40 Fadini GP, Albiero M, Vigili de Kreutzenberg S et al. Diabetes impairs stem cell and proangiogenic cell mobilization in humans. Diabetes Care 2013; 36: 943-949
• 41 Cianfarani F, Toietta G, Di Rocco G et al. Diabetes impairs adipose tissue-derived stem cell function and efficiency in promoting wound healing. Wound Repair Regen 2013; 21: 545-553
• 42 Ghorbani A, Naderi-Meshkin H. The endocrine regulation of stem cells: physiological importance and pharmacological potentials for cell-based therapy. Curr Stem Cell Res Ther 2016; 11: 19-34